{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:58:31Z","timestamp":1696463911140},"reference-count":31,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.vaccine.2010.09.032","type":"journal-article","created":{"date-parts":[[2010,9,26]],"date-time":"2010-09-26T09:43:53Z","timestamp":1285494233000},"page":"8197-8202","source":"Crossref","is-referenced-by-count":3,"title":["Coated cross-species antibodies by mannosamine\u2013biotin adduct confer protection against snake venom without eliciting humoral immune response"],"prefix":"10.1016","volume":"28","author":[{"given":"Tal","family":"Gefen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Pitcovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Vaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soliman","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simi","family":"Krispel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Dan","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gaberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Gorodetsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Aizenshtein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2010.09.032_bib0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602-614.2000","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2010.09.032_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1385\/MB:21:3:225","article-title":"Back to the future: antibody-based strategies for the treatment of infectious diseases","volume":"21","author":"Oral","year":"2002","journal-title":"Mol Biotechnol"},{"issue":"12","key":"10.1016\/j.vaccine.2010.09.032_bib0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2174\/1381612033455189","article-title":"Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers","volume":"9","author":"Buchwald","year":"2003","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.vaccine.2010.09.032_bib0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.coi.2008.06.005","article-title":"Antibodies against viruses: passive and active immunization","volume":"20","author":"Law","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.09.032_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.med.48.1.93","article-title":"Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency","volume":"48","author":"Lee","year":"1997","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.vaccine.2010.09.032_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-7963(96)80060-5","article-title":"Appropriate therapeutic use of immunoglobulin","volume":"10","author":"Stiehm","year":"1996","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1006\/clim.1999.4768","article-title":"Passive antibody therapies: progress and continuing challenges","volume":"93","author":"Casadevall","year":"1999","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.09.032_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1081-1206(10)62794-9","article-title":"Humanized antibodies as potential therapeutic drugs","volume":"81","author":"Vaswani","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2010.09.032_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.vaccine.2010.09.032_bib0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2010.09.032_bib0060","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/bc00032a002","article-title":"Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates","volume":"6","author":"Zalipsky","year":"1995","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2007.06.014","article-title":"Disulfide bridge based PEGylation of proteins","volume":"60","author":"Brocchini","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2010.09.032_bib0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.vaccine.2010.09.032_bib0075","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/107999001317205240","article-title":"Structural and biologic characterization of pegylated recombinant IFN-alpha2b","volume":"21","author":"Grace","year":"2001","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.vaccine.2010.09.032_bib0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1021\/jf000926q","article-title":"Reduced immunogenicity of beta-lactoglobulin by conjugation with carboxymethyl dextran differing in molecular weight","volume":"49","author":"Kobayashi","year":"2001","journal-title":"J Agric Food Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2010.09.032_bib0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1389201033489685","article-title":"Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives","volume":"4","author":"Mehvar","year":"2003","journal-title":"Curr Pharm Biotechnol"},{"issue":"49","key":"10.1016\/j.vaccine.2010.09.032_bib0090","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1016\/j.vaccine.2009.09.010","article-title":"Mannosamine-biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody\u2013antigen interaction","volume":"27","author":"Vaya","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.09.032_bib0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120021113","article-title":"Snake antivenoms","volume":"41","author":"Lalloo","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.09.032_bib0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.toxicon.2004.11.016","article-title":"Presynaptic neuromuscular activity of venom from the brown-headed snake (Glyphodon tristis)","volume":"45","author":"Kuruppu","year":"2005","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0035-9203(01)90339-6","article-title":"An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii)","volume":"95","author":"Ariaratnam","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7475","key":"10.1016\/j.vaccine.2010.09.032_bib0110","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bmj.329.7475.1129","article-title":"Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms","volume":"329","author":"Smalligan","year":"2004","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.vaccine.2010.09.032_bib0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1580\/1080-6032(2003)14[220:SSFAOA]2.0.CO;2","article-title":"Serum sickness following administration of antivenin (Crotalidae) polyvalent in 181 cases of presumed rattlesnake envenomation","volume":"14","author":"LoVecchio","year":"2003","journal-title":"Wilderness Environ Med"},{"key":"10.1016\/j.vaccine.2010.09.032_bib0120","series-title":"The venom database","author":"Fry","year":"1999"},{"issue":"2","key":"10.1016\/j.vaccine.2010.09.032_bib0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/0974-2700.43190","article-title":"Emergency treatment of a snake bite: Pearls from literature","volume":"1","author":"Ahmed","year":"2008","journal-title":"J Emerg Trauma Shock"},{"issue":"24","key":"10.1016\/j.vaccine.2010.09.032_bib0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.5694\/j.1326-5377.1977.tb99311.x","article-title":"Antivenoms: better late than never","volume":"2","author":"Sutherland","year":"1977","journal-title":"Med J Aust"},{"issue":"181","key":"10.1016\/j.vaccine.2010.09.032_bib0135","first-page":"33","article-title":"Poisoning by bites of the saw-scaled or carpet viper Echis carinatus in Nigeria","volume":"46","author":"Warrell","year":"1977","journal-title":"Q J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.169.1.59","article-title":"Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets","volume":"169","author":"Heinzel","year":"1989","journal-title":"J Exp Med"},{"issue":"6512","key":"10.1016\/j.vaccine.2010.09.032_bib0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmj.292.6512.17","article-title":"Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites","volume":"292","author":"Malasit","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"10","key":"10.1016\/j.vaccine.2010.09.032_bib0150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol)\u2013protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2010.09.032_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408449991349168","article-title":"Snake venom hemorrhagins","volume":"29","author":"Hati","year":"1999","journal-title":"Crit Rev Toxicol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10013423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10013423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T04:48:57Z","timestamp":1591937337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10013423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":31,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0264410X10013423"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.09.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}